- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02624999
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
All accrued subjects will be randomized 2:1 to AlloVax™ (CRCL + AlloStim™) immunotherapy vs. standard chemotherapy. AlloVax™ is an experimental individualized therapeutic vaccine shown to be active in this study population.
The standard chemotherapy arm (Arm 1) will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV flurouracil (5FU) on days 1-4 of the cycle.
The immunotherapy arm (Arm 2) will receive immunotherapy (AlloVax™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks.
The study is designed and powered to determine if AlloVax™ is not inferior to the active chemotherapy control.
Tipo di studio
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Bangkok, Tailandia, 10400
- National Cancer Institute of Thailand
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adult males and female subjects aged 18 years or older at screening visit.
- Histopatholologically or cytologically confirmed diagnosis of locoregionally recurrent unresectable or previously untreated metastatic SCCHN.
- Tumor lesion safely accessible for biopsy or surgical excision resulting in a minimum of 0.2 g of tumor sample for CRCL processing.
- Subjects must have measurable disease according to revised RECIST v.1.1 guidelines.
- Eastern Cooperative Oncology Group (ECOG) ≤1.
- Subjects must be screened to be negative for Human Immunodeficiency Virus 1 (HIV1), HBsAg, Hepatitis C (HCV) and Rapid Plasma Reagin (RPR,syphilis).
- Subjects must have adequate organ function including: (WBC >3000/mm3, Platelets >100,000/mm3, Absolute neutrophil count ≥ 1,500/mm³, Hemoglobin ≥ 10.0 g/dL (transfusion allowed)), Hepatic (Serum Total bilirubin < 2 x ULN mg/dL, Alanine transaminase (ALT) (SGPT) / Aspartate aminotransferase (AST) (SGOT) ≤3 x upper limit of normal (ULN)), Renal: Serum creatinine (SCR) <2.0 x ULN, or, Creatinine clearance (CCR) >30 mL/min.
- Pre-study EKG without significant abnormalities.
- Women of child-bearing potential must have a negative urine or serum pregnancy test result within 72 hours prior to the start of study drug administration.
- If child producing potential age, must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product.
- Ability to understand the study, its inherent risks, side effects and potential benefits and be able to give written informed consent to participate.
Exclusion Criteria:
- Clinical evidence or radiological evidence of brain metastasis.
- Treated for another primary cancer within 2 years prior to signing inform consent form.
- Any concomitant anticancer therapies.
- History of severe hypersensitivity to monoclonal antibody drugs or any contraindication to any of the study drugs.
- Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis).
- Prior experimental therapy or cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine).
- Clinical requirement for systemic steroids or immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month prior to signing inform consent form.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, requiring parenteral antibiotics, symptomatic congestive heart failure, severe myocardial insufficiency, cardiac arrhythmia. All infections must be resolved and the subject must remain a febrile for seven days prior to being placed in the study.
- History of blood transfusion reactions.
- Psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation.
- Female subject is pregnant or breast-feeding
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Immunotherapy
Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
|
AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
Altri nomi:
|
Comparatore attivo: Standard chemotherapy
Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
|
Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Safety and tolerability (vital signs, physical examination, clinical laboratory profile, adverse events assessed by CTCAE v4.0 and dose limiting toxicity (DLT))
Lasso di tempo: 119 days
|
Whether AlloVax™ is less toxic than chemotherapy.
will be evaluated on the basis of the following parameters: vital signs, physical examination, clinical laboratory profile, adverse events assessed by CTCAE v4.0 and dose limiting toxicity (DLT)
|
119 days
|
Overall Survival
Lasso di tempo: 119 days
|
Whether AlloVax™ is not inferior to the active chemotherapy control (from time of randomization).
Subjects are followed for survival during the trial and as long as they are alive after the last study treatment through follow-up
|
119 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Health related Quality of Life (HRQoL)
Lasso di tempo: 119 days
|
QLQ-C30 and QLQ-H&N35 questionnaires
|
119 days
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
RECIST
Lasso di tempo: 119 days
|
Response and correlation with pathology assessment
|
119 days
|
Immune-Related Response Criteria (irRC)
Lasso di tempo: 119 days
|
Response and correlation with pathology assessment
|
119 days
|
Immune response in the treatment arm
Lasso di tempo: 119 days
|
Correlation of OS with immune response
|
119 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Michael Har-Noy, Dr., CEO & CTO
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ITL-020-HENK-VAXPII
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su AlloVax™
-
Immunovative Therapies, Ltd.RitiratoCarcinoma epatocellulareIsraele
-
Immunovative Therapies, Ltd.CompletatoCarcinoma epatocellulare adulto avanzatoTailandia
-
Immunovative Therapies, Ltd.CompletatoCarcinoma a cellule squamose della testa e del collo | Cancro della testa e del colloTailandia
-
BaroNova, Inc.Completato
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalSconosciutoEpilessia del lobo temporale
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalSconosciutoDanno cerebrale, cronico | Cerebellar Cognitive Affective Syndrome | Mutismo cerebellare
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletatoGestione delle vie aeree | Maschera laringea delle vie aeree | Intubazione con fibre ottiche
-
Boston Scientific CorporationCompletatoAttacco ischemico transitorio | Ictus tromboembolico | Prevenzione dell'ictusStati Uniti, Argentina, Germania
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting, Inc.ReclutamentoIdrocefalo | Idrocefalo, ComunicanteArgentina
-
Aubrey Inc.SconosciutoTrattamento delle ustioni del sito donatoreStati Uniti